Newsletter SignupSearch

Cross-Platform Evaluation of Commercial Metabolomics Platforms to Support Precision Therapeutics Research

As part of its RAPID-DxTM (Research Alliance for Precision Therapeutics, Innovation and Diagnostics) program, researchers from Cohen Veterans Bioscience (CVB) and collaborators conducted a blinded cross-platform analysis (or "bakeoff") of commercially available assay platforms to inform selection in the conduct of neuropsychiatric biomarker research.

Share this article:

More from CVB

American Brain Coalition Selects Cohen Veterans Bioscience Executive as New Board Member

New Artificial-Intelligence-based Tools for Monitoring Parkinson’s Disease using Wearable Devices

Peter Hoehn, Accomplished Pharmaceutical Executive, Joins Cohen Veterans Bioscience (CVB) in Newly Created Executive Leadership Role

About Cohen Veterans Bioscience (CVB)

Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.